Revive Therapeutics · CSE: RVV
Revive Therapeutics
Status: NotRated · held Verified security: CSE RVV. The March filing also describes historical TSX Venture RVV, Frankfurt 31R and U.S. RVVTF trading, but the current August CSE filing verifies only the CSE symbol. The supplied RVV.V and current OTC/Frankfurt venue status remain unverified. Financial evidence date: March 31, 2026, with CSE financing and listed-capital evidence through August 6, 2026. Currency is Canadian dollars.
Revive is a pre-revenue life-sciences company pursuing drug-repurposing and delivery technologies across several programs, including cannabinoid and psychedelic applications. Its March 2026 CSE-filed financial statements and MD&A say the drug-delivery platform is intended to deliver cannabinoids through topical or buccal routes. The evidence does not establish a funded, near-commercial cannabinoid program: research spending for drug-delivery technology was nil for both the quarter and nine months, and previously recorded psilocybin and psilocin intangibles had been fully impaired to nil because management did not foresee revenue.
The balance sheet makes financing dependence the central risk. At March 31, Revive reported only $12,665 of unrestricted cash, $149,326 of current assets and a $4.005 million working-capital deficiency. Accounts payable and accrued liabilities were $4.155 million, so cash represented roughly 0.3% of that balance. The deficiency had widened by $559,686, or 16.2%, from June 2025. Nine-month operating cash use was $150,695, almost completely offset by $148,800 of financing proceeds; comprehensive loss was $1.027 million. The filing includes a going-concern warning and states that existing working capital was insufficient for planned development activity.
Capital issuance continued after quarter-end. The August 6 CSE Form 7 records a first financing tranche of 7,716,250 units for $246,920, or $0.032 per unit. Each unit included one common share and one warrant. Outstanding listed securities rose from 435,676,173 at March 31 to 443,392,423, a 1.77% increase. At March 31, another 40.471 million warrants, 100,000 broker warrants and 42.465 million options represented potential overhang equal to about 19.1% of then-outstanding shares, before considering the July warrants or subsequent expiries.
The financial filing says the company had earned no operating revenue. Its remaining investments were valued at $131,762, mostly illiquid Level 3 holdings, which should not be treated as dependable funding for clinical development.
Conclusion: NotRated · held. CIN issues no current rating, price target, reference quote or upside. A qualified valuation requires the June 2026 annual accounts, current cash and liabilities, a post-financing option/warrant register, current venue confirmation, and original evidence defining cannabinoid rights, development budget, clinical milestones and commercialization economics.
Greenlane Holdings · Nasdaq: GNLN
Greenlane Holdings
Status: NotRated · held Verified security: Nasdaq Class A common stock GNLN, as identified in the company’s October 15, 2026 Form 8-K. Financial evidence date: June 30, 2026, with subsidiary-assignment evidence through October 15, 2026. Currency is U.S. dollars; financial-statement figures are in thousands unless stated otherwise.
Greenlane is no longer a conventional cannabis-accessories distributor. Its June 2026 issuer-hosted Form 10-Q shows that the company had shifted toward a digital-asset treasury strategy centered on BERA and related instruments while legacy wholesale operations were being wound down. Six-month net revenue fell to $109,000 from $2.257 million, and staking and yield revenue was $729,000. The company recorded a $43.0 million net loss, including a $32.0 million non-cash fair-value loss on digital assets.
At June 30, cash and cash equivalents were $6.065 million, stablecoin-related protocol instruments were $8.057 million, and digital assets were $16.442 million. Those two non-cash treasury categories represented about 76.5% of total assets. The digital-asset balance had fallen 55.0% from December, and $6.922 million, or 42.1%, of June digital-asset fair value was restricted. Current assets of $15.444 million exceeded current liabilities of $6.543 million by $8.901 million, and the filing reported no outstanding debt. However, six-month operating cash use was $7.098 million. A simple cash-to-historical-burn calculation is about 5.1 months; it is not a runway forecast because the operating perimeter changed after June and protocol instruments carry liquidity, counterparty, smart-contract and governance risks.
The September restructuring removes the legacy cannabis-distribution business from the parent’s control. The October 7 Form 8-K says four subsidiaries assigned substantially all assets for creditor liquidation, and the parent received no consideration. Their liabilities were not released. The parent and three named entities were not assignors, but the filing warned that claims could still be asserted against them. The October 15 Form 8-K confirms four court proceedings and leaves their outcomes unresolved. June pro forma information cannot establish September or current parent cash, retained guarantees, recoveries or claims.
Class A shares increased to 694,544 at June 30 and August 12 from 603,696 at December 31, a 15.0% rise after giving effect to reverse splits. That historical count is not a current fully diluted denominator, and the unused ATM capacity is not cash.
Conclusion: NotRated · held. CIN issues no current rating, price target, reference quote or upside. A valuation requires September-quarter parent-only accounts, current cash and token holdings with transfer restrictions, assignment claims and retained guarantees, current shares and dilutive securities, recurring parent costs, and evidence of any continuing material cannabinoid economics.
RYTHM · Nasdaq: RYM
RYTHM
Status: NotRated · held. RYTHM, Inc. identifies its common stock as Nasdaq: RYM and says the name change became effective September 2, 2025. That establishes the reviewed security; it does not validate the separate AGRS directory lead. The business now combines THC brand licensing with hemp-derived beverages after exiting extraction operations. This is an initial company review, not a completed valuation, and rating, target, reference quote and upside remain null.
The June 30, 2026 Form 10-Q reports first-half revenue of $36.307 million: $27.475 million of licensing revenue and $8.832 million of non-licensing revenue. Related parties generated $27.7 million, or 76.3% of the total. Gross profit was $28.933 million, but licensing revenue has no reported cost of goods sold; the beverage gross margin was only 16.5% ($1.458 million on $8.832 million). The March amendment replaced royalties with a $70 million annual cash fee from Green Thumb affiliates effective April 1. An October 13 executed amendment adds Señorita IP while specifying $64.25 million for one license in 2026. These figures cannot be stacked into a current aggregate run rate without reconciling every contract, term and termination right.
First-half net income was $21.106 million, but included a $26.798 million noncash tax benefit. The filing’s two-class method allocates $17.638 million to participating pre-funded warrants, leaving $3.468 million for common holders; divided by 2.152 million weighted shares, that reproduces $1.61 basic EPS. Operating cash flow was $9.697 million and benefited from roughly $5.6 million of operating asset and liability movements, so neither headline earnings nor cash flow is a clean recurring base.
June cash was $41.915 million versus $72.0 million of related-party current debt and $8.623 million of other current debt, a $38.708 million cash deficit before other current liabilities. Basic shares were 2.179 million. Adding 11.034 million warrants, 2.971 million note-conversion shares, 128,250 unvested RSUs and 75 options produces a mechanical 16.313 million count—7.5 times basic shares—but it is not a fully diluted valuation denominator. Converting debt requires removing the corresponding claim, and actual exercises, accrued-interest instruments and service-payment elections remain unknown.
The thesis is therefore concentration plus capital optionality, not simply a high-margin royalty stream. Catalysts are verified cash collection, durable license economics, beverage margin improvement and orderly debt settlement without disproportionate dilution. Falsifiers are counterparty stress, adverse hemp regulation, termination or impairment of licensed rights, or refinancing that shifts value from common holders. Before any target, obtain the complete amended license set, post-October exercises and conversions, current share register, debt settlement terms, regulatory originals, and a separated beverage/license cost and reinvestment model. Author holdings and relationships remain unknown.